Revvity (RVTY) Projected to Announce Quarterly Earnings on Tuesday

Key Points

• Revvity is expected to report Q3 2026 earnings before the market opens on November 3. Analysts forecast $1.30 in earnings per share and $694.73 million in revenue, compared with full-year guidance of $5.30–$5.40 EPS.
• In the prior quarter, Revvity earned $1.41 per share, exceeding estimates by $0.20, while revenue of $729.69 million surpassed forecasts but declined 1.3% year over year.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $124.43. The company also declared a quarterly dividend of $0.07 per share, representing a 0.2% yield.

Revvity (NYSE:RVTY - Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of $1.30 per share and revenue of $694.73 million for the quarter. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Parties may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same period in the prior year, the firm posted $1.18 EPS. The company's revenue was down 1.3% on a year-over-year basis. On average, analysts expect Revvity to post $5.36 EPS for the current fiscal year and $5.92 EPS for the next fiscal year.

Revvity Price Performance

Revvity stock opened at $160.43 on Tuesday. Revvity has a 1 year low of $81.22 and a 1 year high of $166.25. The firm has a 50 day moving average price of $140.14 and a 200 day moving average price of $110.69. The company has a market cap of $17.90 billion, a price-to-earnings ratio of 29.68, a PEG ratio of 2.89 and a beta of 1.06. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity's dividend payout ratio (DPR) is currently 13.33%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Zacks Research upgraded shares of Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Barclays boosted their price objective on shares of Revvity from $115.00 to $160.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. William Blair started coverage on Revvity in a report on Monday, October 5th. They set an "outperform" rating for the company. KeyCorp upped their price objective on Revvity from $125.00 to $165.00 and gave the stock an "overweight" rating in a report on Friday, September 4th. Finally, Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. Five investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $124.43.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of Revvity stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the transaction, the insider directly owned 6,635 shares of the company's stock, valued at $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider directly owned 14,781 shares in the company, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 9,045 shares of company stock valued at $1,281,439. Corporate insiders own 0.85% of the company's stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.